

****Published January 2013****

MarketVIEW: Alzheimers disease vaccines (CAT: VAMV041)

Product Name	:	MarketVIEW: Alzheimer's disease vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 1 forecast model
Therapeutic Area	:	Novel vaccines
Publication date	:	January 2013
Catalogue No	:	VAMV041

Background

Alzheimer's disease is the most common form of dementia first described by German neurologist Alois Alzhemier in 1906. It is an irreversible, progressive brain disease that destroys cognitive skills such as memory and thinking ability rendering sufferers unable to carry out even simple tasks. In 2010, there were an estimated 35.6m people living with dementia worldwide of which Alzheimer's disease accounted for 60-70% of cases. There is currently no cure for Alzheimer's disease and treatments are concentrated on the management of symptoms.

Prospects for an immunotherapeutic Alzheimer's disease vaccine look to be positive because both active and passive vaccinations have been shown to have a positive effect on beta-amyloid in the brain. Currently, the most promising Alzheimer's vaccine candidate is CAD106 (Phase II) which is being developed by Novartis and Cytos.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Alzheimer's vaccines across major Western¹ markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions per product type (therapeutic + prophylatic) along with timeframe, pricing and penetration estimates for all adult risk groups depending on Alzheimer's disease severity. The product also includes an up-to-date review of disease epidemiology and competitor R&D pipeline activity.

¹ US, Canada, Australia, UK, France, Italy, Germany, Spain and Japan

Methodology

VacZine Analytics has closely monitored all significant source material pertaining Alzheimer's disease epidemiology, disease indications and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

PRODUCT CONTENTS:

Published January 2013 (CAT No: VAMV041)

****This product is composed of a model and summary presentation

Author's note

Executive Summary

Commercial model: key outputs

Alzheimer's disease vaccine: available market to 2030

Alzheimer's disease vaccine: predicted demand to 2030

Alzheimer's disease vaccine: available US market to 2030 (high case)

Alzheimer's disease vaccine: available US market to 2030 (lo case)

Alzheimer's disease vaccine: available EU + other markets to 2030 (high case)

Alzheimer's disease vaccine: available EU + other markets to 2030 (lo case)

Alzheimer's disease: disease background and epidemiology

Alzheimer's disease: brief disease background

Alzheimer's disease: symptoms

Alzheimer's disease: stages

Alzheimer's disease: global epidemiology – overview

Alzheimer's disease: global epidemiology – prevalence by age

Alzheimer's disease: US epidemiology

Alzheimer's disease: UK epidemiology

Alzheimer's disease: diagnosis

Alzheimer's disease: treatment pathway

Alzheimer's disease: treatment overview

Alzheimer's disease: treatment options

Alzheimer's disease: effectiveness of treatment

Alzheimer's disease: financial impact of the disease

Alzheimer's disease: cost of treatment

Alzheimer's disease: financial impact of the disease US

Alzheimer's disease: financial impact of the disease UK

Alzheimer's disease: indirect costs

Alzheimer's disease: future impact

Alzheimer's disease vaccine: modeling commercial potential

The role of an Alzheimer's disease vaccine

Current status of the vaccine

Pipeline summary

Alzheimer's disease vaccine forecast model

Forecast vaccine population flow

Alzheimer's disease vaccine: target product profile

Continued.....

Commercial model assumptions (Lo/base/hi)
Commercial model assumptions by country (Lo/base/hi)
Bibliography
Disclaimer
About **VacZine Analytics**

PAGES: ~65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand models (MS Excel-based)

Title sheet
TOTAL CHARTS
CHARTS – VALUE (high)
CHARTS – VALUE (base)
CHARTS – VALUE (low)
CHARTS – VOLUME (high)
CHARTS – VOLUME (base)
CHARTS – VOLUME (low)
Value summary (Total market)
Volume summary (Total market)
US (high)
Canada (high)
UK (high)
Germany (high)
France (high)
Spain (high)
Italy (high)
Australia (high)
Japan (high)
US (base)
Canada (base)
UK (base)
Germany (base)
France (base)
Spain (base)
Italy (base)
Australia (base)
Japan (base)
US (low)
Canada (low)
UK (low)
Germany (low)
France (low)
Spain (low)
Italy (low)
Australia (low)
Japan (low)
Worksheets = 65 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$8995.00/ GBP £5620.00[#] (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. Alzheimer's Disease Fact Sheet. Available at <http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet>. Accessed October 2012
2. Alzheimer's Disease. Available at : http://www.medicinenet.com/alzheimers_disease_causes_stages_and_symptoms/article.htm. Accessed October 2012
3. Symptoms of Alzheimer's disease. Available at <http://www.nhs.uk/Conditions/Alzheimers-disease/Pages/Symptoms.aspx> Accessed October 2012
4. Dementia: A Public Health Priority, Report published by WHO 2012;
5. Reitz *et al.*, Epidemiology of Alzheimer Disease: Risk and Protective Factors, *Nat Rev Neurol.* 2011;7(3)
6. Falkenstein, Epidemiology of Alzheimer's disease . Available at: www.pitt.edu/~super7/9011-10001/9341.ppt. Accessed November 2012
7. 2012 Facts and Figures; Alzheimer's disease facts and figures. Available at http://www.alz.org/downloads/facts_figures_2012.pdf; Accessed October 2012
8. Miniño A, Murphy SL, Xu J, Kochanek K. Deaths: Final Data for 2008. National Vital Statistics Reports, Hyattsville, Md.;
9. Statistics. Available at http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=341. Accessed October 2012
10. Luengo-Fernandez *et al.*, Dementia 2010 – The economic burden of dementia and associated research funding in the United Kingdom, www.dementia2010.org;
11. Dementia Statistics. Available at http://www.alzheimersresearchuk.org/siteFiles/resources/documents/ARUK_Dementia_statistics_2012.pdf. Accessed October 2012
12. Drug treatments for Alzheimer's disease. Available at http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=147. Accessed November 2012
13. Tiedeman *et al.*, (2011) Alzheimer's disease: Current treatment options and future developments, <http://formularyjournal.modernmedicine.com/formulary/article/articleDetail.jsp?id=734408>;
14. Ballard *et al.*, (2011) Nonpharmacological treatment of Alzheimer disease. *Can J Psychiatry.* 2011 Oct;56(10):589-95
15. Dementia, Diagnosis and Treatment Guideline. Available at <https://www.ghc.org/all-sites/guidelines/dementia.pdf>. Accessed November 2012
16. Rockwood *et al.*, (2007) The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial, *BMC Neurology* 2007, 7:26
17. Luengo-Fernandez *et al.*, Dementia 2010 – The economic burden of dementia and associated research funding in the United Kingdom, www.dementia2010.org;
18. Financial cost of dementia. Available at http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=418. Accessed November 2012
19. Alzheimer's disease to cost united states \$20 trillion over next 40 years. Available at http://www.alz.org/documents_custom/final_trajectory_report_release-emb_5-11-10.pdf. Accessed November 2012
20. Thomas *et al.*, Immunotherapy and Alzheimer's disease, *The Journal of Quality Research in Dementia*, Issue 4
21. Treatment Horizon. Available at http://www.alz.org/research/science/alzheimers_treatment_horizon.asp. Accessed November 2012
22. Elan's AN1792: No Clinical Benefit With Clearance of Amyloid Plaques in AD. Available at <http://bmartinmd.com/2008/07/elans-an1792-no-clinical-benef.html>; Accessed December 2012
23. Pfizer, J&J Alzheimer's drug bapineuzumab flunks out in big PhIII. Available at <http://www.fiercebiotech.com/story/jj-pfizer-report-ominous-phiii-failure-bapineuzumab-alzheimers-study/2012-07-23>. Accessed December 2012
24. Novartis, Cytos Alzheimer's vax shows immune response. Available at <http://www.fiercevaccines.com/story/novartis-cytos-alzheimers-vax-shows-immune-response/2012-06-14>. Accessed December 2012
25. Early steps toward an Alzheimer's vaccine. Available at <http://www.health.harvard.edu/blog/early-steps-toward-an-alzheimers-vaccine-201206124878>. Accessed December 2012
26. Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients. Available at <http://www.clinicaltrials.gov/ct2/show/NCT01097096?term=cad106&rank=1>; Accessed December 2012
27. Novartis – CAD106 – For The Treatment Of Alzheimer's Disease. Available at <http://www.pharmaceutical-networking.com/novartis-cad106-for-the-treatment-of-alzheimer%E2%80%99s-disease/>. Accessed December 2012
28. AFFiRiS website. Available at http://www.affiris.com/html/en/impfstoffe/morbus_alzheimer_impfstoffe.html. Accessed January 2013
29. Safety and Tolerability of AFFITOPE AD03. Available at <http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01309763>. Accessed January 2013

30. Imbimbo *et al.*, Solanezumab for the treatment of mild-to-moderate Alzheimer's disease, [Expert Rev Clin Immunol](#), 2012 Feb;8(2):135-49.
31. Nuron website. Available at <http://www.nuronbiotech.com/pipeline/vaccines/>. Accessed January 2013

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009